INS and diabetes mellitus: Thus, DS20060511 may act as an antidiabetic agent with an entirely novel mechanism of action in patients with impaired actions of insulin in the skeletal muscle and those with either type 1 or 2 diabetes receiving insulin and/or exercise therapy.